- Home
- CHMI vs HOWL Comparison
CHMI vs HOWL Comparison
Compare CHMI & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHMI
- HOWL
- Stock Information
- Founded
- CHMI 2012
- HOWL 2017
- Country
- CHMI United States
- HOWL United States
- Employees
- CHMI N/A
- HOWL N/A
- Industry
- CHMI Real Estate Investment Trusts
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- CHMI Real Estate
- HOWL Health Care
- Exchange
- CHMI Nasdaq
- HOWL Nasdaq
- Market Cap
- CHMI 96.0M
- HOWL 53.4M
- IPO Year
- CHMI 2013
- HOWL 2021
- Fundamental
- Price
- CHMI $2.84
- HOWL $1.07
- Analyst Decision
- CHMI Hold
- HOWL Strong Buy
- Analyst Count
- CHMI 2
- HOWL 3
- Target Price
- CHMI N/A
- HOWL $8.33
- AVG Volume (30 Days)
- CHMI 335.8K
- HOWL 610.4K
- Earning Date
- CHMI 08-07-2025
- HOWL 08-07-2025
- Dividend Yield
- CHMI 21.13%
- HOWL N/A
- EPS Growth
- CHMI N/A
- HOWL N/A
- EPS
- CHMI N/A
- HOWL N/A
- Revenue
- CHMI $27,506,000.00
- HOWL $1,143,000.00
- Revenue This Year
- CHMI N/A
- HOWL N/A
- Revenue Next Year
- CHMI $54.92
- HOWL N/A
- P/E Ratio
- CHMI N/A
- HOWL N/A
- Revenue Growth
- CHMI 19.59
- HOWL N/A
- 52 Week Low
- CHMI $2.34
- HOWL $0.60
- 52 Week High
- CHMI $3.95
- HOWL $4.18
- Technical
- Relative Strength Index (RSI)
- CHMI 44.15
- HOWL 43.95
- Support Level
- CHMI $2.68
- HOWL $1.02
- Resistance Level
- CHMI $3.03
- HOWL $1.12
- Average True Range (ATR)
- CHMI 0.08
- HOWL 0.09
- MACD
- CHMI -0.02
- HOWL -0.03
- Stochastic Oscillator
- CHMI 45.71
- HOWL 16.67
About CHMI Cherry Hill Mortgage Investment Corporation
Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.